RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
XSpray Pharma AB (publ) Stock

XSpray Pharma AB (publ) Net Income 2025

XSpray Pharma AB (publ) Net Income

-49.57 M SEK

Ticker

XSPRAY.ST

ISIN

SE0009973563

WKN

A2H48J

In 2025, XSpray Pharma AB (publ)'s profit amounted to -49.57 M SEK, a -74.88% increase from the -197.36 M SEK profit recorded in the previous year.

The XSpray Pharma AB (publ) Net Income history

YEARNET INCOME (undefined SEK)
2028e-
2027e-
2026e675.33
2025e-49.57
2024e-197.36
2023-179.67
2022-131.67
2021-96.7
2020-52.41
2019-45.77
2018-23.1
2017-13.82
2016-4.1
2015-12.09

XSpray Pharma AB (publ) Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into XSpray Pharma AB (publ), a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by XSpray Pharma AB (publ) from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects XSpray Pharma AB (publ)’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of XSpray Pharma AB (publ). Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into XSpray Pharma AB (publ)’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing XSpray Pharma AB (publ)’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on XSpray Pharma AB (publ)’s growth potential.

XSpray Pharma AB (publ) Revenue, EBIT and net profit per share

DateXSpray Pharma AB (publ) RevenueXSpray Pharma AB (publ) EBITXSpray Pharma AB (publ) Net Income
2028e2.1 B undefined0 undefined0 undefined
2027e2.16 B undefined0 undefined0 undefined
2026e1.63 B undefined811.54 M undefined675.33 M undefined
2025e503.49 M undefined-86.86 M undefined-49.57 M undefined
2024e2.53 M undefined-247.45 M undefined-197.36 M undefined
20230 undefined-180.77 M undefined-179.67 M undefined
20220 undefined-115.91 M undefined-131.67 M undefined
20210 undefined-96.3 M undefined-96.7 M undefined
20200 undefined-53.46 M undefined-52.41 M undefined
20190 undefined-46.56 M undefined-45.77 M undefined
2018277,000 undefined-23.22 M undefined-23.1 M undefined
2017332,000 undefined-13.9 M undefined-13.82 M undefined
2016792,000 undefined-4.06 M undefined-4.1 M undefined
20153.64 M undefined-12.09 M undefined-12.09 M undefined

XSpray Pharma AB (publ) stock margins

The XSpray Pharma AB (publ) margin analysis displays the gross margin, EBIT margin, as well as the profit margin of XSpray Pharma AB (publ). The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for XSpray Pharma AB (publ).

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the XSpray Pharma AB (publ)'s sales revenue. A higher gross margin percentage indicates that the XSpray Pharma AB (publ) retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the XSpray Pharma AB (publ)'s earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the XSpray Pharma AB (publ)'s total revenue generated. When comparing the revenue margin year over year, investors can gauge the XSpray Pharma AB (publ)'s growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the XSpray Pharma AB (publ). Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the XSpray Pharma AB (publ)'s financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

XSpray Pharma AB (publ) Margin History

XSpray Pharma AB (publ) Gross marginXSpray Pharma AB (publ) Profit marginXSpray Pharma AB (publ) EBIT marginXSpray Pharma AB (publ) Profit margin
2028e2,539.9 %0 %0 %
2027e2,539.9 %0 %0 %
2026e2,539.9 %49.67 %41.33 %
2025e2,539.9 %-17.25 %-9.85 %
2024e2,539.9 %-9,800 %-7,816.28 %
20232,539.9 %0 %0 %
20222,539.9 %0 %0 %
20212,539.9 %0 %0 %
20202,539.9 %0 %0 %
20192,539.9 %0 %0 %
20182,539.9 %-8,381.59 %-8,338.63 %
20172,539.9 %-4,185.54 %-4,161.75 %
20162,539.9 %-512.5 %-517.3 %
2015-162.86 %-332.09 %-332.17 %

XSpray Pharma AB (publ) Aktienanalyse

What does XSpray Pharma AB (publ) do?

XSpray Pharma AB (publ) was founded in Sweden in 2003 and is headquartered in Stockholm. The company specializes in the development and manufacturing of pharmaceutical products tailored to the needs of patients with unique medical challenges. The business model of XSpray Pharma is based on patenting and selling its MicroSpray technology platform, which allows drugs to be transformed into a microfine spray form, thereby improving bioavailability, duration, and intensity of action. The company has three main divisions: - The first division is contract research, where XSpray Pharma licenses its technology platform to other pharmaceutical companies and assists them in drug development. - The second division is the development of its own medications, where XSpray Pharma develops innovative therapies for rare diseases. The company works closely with patient organizations, doctors, and scientists to better understand patient needs and address their medical challenges. - The third division is partnership with other pharmaceutical companies, where XSpray Pharma contributes its technology platform and drug development expertise to collaboratively develop and market innovative therapies. One of XSpray Pharma's key products is APT-1011, a spray for severe nausea and vomiting in cancer patients that acts quickly and effectively due to its microfine nature. It has received European approval (EMA) and is being submitted in the US in collaboration with US pharmaceutical company RedHill Biopharma. Another important product is APT-1026, a spray for the treatment of hypersensitivity reactions. It is currently in development and is intended to help patients with various types of hypersensitivity reactions in the future. In addition, XSpray Pharma has several patented technology platforms and a wide range of drug candidates in the pipeline. The company works closely with its partners to leverage its technology and expertise in drug development to jointly create innovative therapies for patients. In recent years, XSpray Pharma has received several awards and recognitions for its innovative technology and drug development, including the Swedish Pharma Prize and the European Mediscience Award. In summary, XSpray Pharma is an innovative pharmaceutical company specializing in the development of drugs for patients with unique medical challenges. The company has utilized its MicroSpray technology platform and drug development expertise to develop a wide range of drug candidates in the pipeline aimed at improving the lives of patients. XSpray Pharma AB (publ) ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Net Income Details

Understanding XSpray Pharma AB (publ)'s Profit Margins

The profit margins of XSpray Pharma AB (publ) represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of XSpray Pharma AB (publ)'s financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.

Year-to-Year Comparison

Evaluating XSpray Pharma AB (publ)'s profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.

Impact on Investments

XSpray Pharma AB (publ)'s profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.

Interpreting Profit Fluctuations

When XSpray Pharma AB (publ)’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.

Frequently Asked Questions about XSpray Pharma AB (publ) stock

How much profit has XSpray Pharma AB (publ) made this year?

XSpray Pharma AB (publ) has made -49.57 M SEK this year.

How has the profit developed compared to last year?

The profit has increased by -74.88% compared to last year fallen

What impact do the earnings have on the shareholders?

An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.

How does XSpray Pharma AB (publ) publish its earnings?

XSpray Pharma AB (publ) publishes its earnings in the form of quarterly or annual reports.

Which financial indicators are included in the quarterly or annual reports?

The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.

Why is it important for investors to know the earnings of XSpray Pharma AB (publ)?

The profits of XSpray Pharma AB (publ) are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.

How can one learn more about the earnings of XSpray Pharma AB (publ)?

You can learn more about the earnings of XSpray Pharma AB (publ) by reviewing the quarterly or annual reports or following the company presentations.

How much dividend does XSpray Pharma AB (publ) pay?

Over the past 12 months, XSpray Pharma AB (publ) paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, XSpray Pharma AB (publ) is expected to pay a dividend of 0 SEK.

What is the dividend yield of XSpray Pharma AB (publ)?

The current dividend yield of XSpray Pharma AB (publ) is .

When does XSpray Pharma AB (publ) pay dividends?

XSpray Pharma AB (publ) pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of XSpray Pharma AB (publ)?

XSpray Pharma AB (publ) paid dividends every year for the past 0 years.

What is the dividend of XSpray Pharma AB (publ)?

For the upcoming 12 months, dividends amounting to 0 SEK are expected. This corresponds to a dividend yield of 0 %.

In which sector is XSpray Pharma AB (publ) located?

XSpray Pharma AB (publ) is assigned to the 'Health' sector.

Wann musste ich die Aktien von XSpray Pharma AB (publ) kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of XSpray Pharma AB (publ) from 1/8/2025 amounting to 0 SEK, you needed to have the stock in your portfolio before the ex-date on 1/8/2025.

When did XSpray Pharma AB (publ) pay the last dividend?

The last dividend was paid out on 1/8/2025.

What was the dividend of XSpray Pharma AB (publ) in the year 2024?

In the year 2024, XSpray Pharma AB (publ) distributed 0 SEK as dividends.

In which currency does XSpray Pharma AB (publ) pay out the dividend?

The dividends of XSpray Pharma AB (publ) are distributed in SEK.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von XSpray Pharma AB (publ)

Our stock analysis for XSpray Pharma AB (publ) Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of XSpray Pharma AB (publ) Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.